CytoSorbents (NASDAQ: CTSO) Delivers Q4 and Full Year 2025 Results: Strategic Restructuring, Regulatory Progress, and Path to Cash Flow Breakeven

Key Financial Highlights

• 2025 Revenue: \$37.1 million, up 4% year-over-year, supported by strong growth outside Germany and among distributors.
• Gross Margin: Increased to 71% for the full year, with Q4 2025 gross margin expanding to 74% compared to 70% in Q4 2024.
• Operating Loss: Improved by 10% to \$14.7 million (from \$16.5 million in 2024).
• Net Loss: Improved to \$8.2 million or \$0.13 per share (from a net loss of \$20.7 million or \$0.38 per share in 2024).
• Adjusted Net Loss: \$14.2 million or \$0.23 per share (compared to \$12.7 million or \$0.23 per share in 2024).
• Adjusted EBITDA Loss: Improved to \$10.5 million (from \$11.5 million in 2024).
• Year-End Cash Position: \$7.8 million in cash, cash equivalents, and restricted cash as of December 31, 2025.
• Credit Facility: \$2.5 million in additional proceeds secured in November 2025, with extended interest-only period through end of 2026.

Strategic Actions and Operational Update

• Cost Reduction: In Q4 2025, CytoSorbents implemented a strategic workforce reduction, cutting headcount by 10% and realigning expenses, with a \$0.5 million restructuring charge.
• Production Efficiencies: Achieved a solid quarter of production efficiencies, increasing inventory buffer, enabling reduced production expenditures for 2026, and further decreasing cash burn.
• Cash Flow Breakeven Path: Company now anticipates reaching cash flow breakeven in the second half of 2026.

Sales Performance Detail

• Direct Sales Outside Germany: Up 13% to \$8.6 million.
• Distributor Sales: Increased 11.4% to \$16.5 million. Combined, these channels represent 68% of total business.
• Germany: Sales declined 10% to \$11.8 million, reflecting ongoing restructuring and new strategies to drive scalable growth. Early 2026 indicators show improved commercial activity and customer engagement.

Clinical and Market Momentum

• Milestone: Surpassed 300,000 cumulative CytoSorb^® treatments delivered globally, up over 50% in recent years, across 70+ countries.
• Sepsis and Septic Shock: New multinational surveys and clinical studies reinforce CytoSorb as the leading and preferred modality for blood purification in refractory septic shock, with evidence of improved hemodynamics and reduced mortality.
• Other Indications:
  • Acute Liver Failure: Significant reductions in bilirubin, higher transplant listing and survival rates.
  • Cardiogenic Shock: Over 50% reduction in vasoactive-inotropic score, improved hemodynamics.
  • Cardiac Surgery: Lower rates of acute kidney injury, improved renal outcomes, shorter ICU stays, and reduced severe bleeding in high-risk populations (e.g., infective endocarditis, heart transplantation, patients on blood thinners).
• Device Expansion: Over 100 PuriFi^® hemoperfusion pumps placed internationally, expanding infrastructure and expected to drive future device and disposables use. Launch of HotSwap™ for easier cartridge exchange.

DrugSorb^®-ATR Regulatory and Market Update

• Regulatory Progress: Following an initial FDA De Novo denial in April 2025 for DrugSorb-ATR (for reducing serious perioperative bleeding in CABG patients on Brilinta^®/ticagrelor), the FDA confirmed device safety but requested additional labeling data. CytoSorbents is preparing a new De Novo application, incorporating recent STAR Registry real-world evidence and STAR-T trial data.
• FDA Engagement: Ongoing interactive discussions to finalize application requirements. Submission timing update expected once finalized. Post-submission, a regulatory decision is expected within a typical 150-day review period.
• Published Data: U.S. and Canadian pivotal STAR-T trial results published in the Journal of Thoracic and Cardiovascular Surgery (2026), reinforcing safety and efficacy of intraoperative DrugSorb-ATR use.
• International Adoption: CytoSorb is already approved in the EU for intraoperative removal of Brilinta^®, Xarelto^®, and other antithrombotics. Real-world data show low severe bleeding rates and no device-related adverse events, even with urgent surgery within 24 hours of last dose.
• Market Dynamics: Generic ticagrelor launched in U.S. mid-2025, expected to boost use in heart attack patients and increase the patient pool for DrugSorb-ATR. The withdrawal of Andexxa^® (the only approved reversal agent for certain DOACs) from the U.S. market in December 2025 underscores the unmet need for CytoSorbents’ technology.
• Thought Leadership: Multiple presentations at upcoming major cardiology conferences (EuroPCR, ESC Congress, EACTS Annual Meeting) highlight ongoing evidence generation and visibility within the cardiovascular community.

Other Noteworthy Developments

• Balance Sheet and Capital Structure: Rights warrant offering and amended credit facility provided additional liquidity in 2025. Inventory buffer allows for lower production spending in 2026.
• Product Portfolio: Multiple products and product candidates protected by patents and trademarks. DrugSorb-ATR under active regulatory pursuit in U.S. and Canada.

Potential Share Price Drivers and Risks

• Upcoming FDA De Novo submission and a potential U.S. approval for DrugSorb-ATR are major catalysts.
• Restructuring and cost reduction efforts position the company for improved financial performance and a possible return to cash flow breakeven in H2 2026.
• Continued strong growth outside Germany, improved clinical and real-world evidence, and expanding device use globally could support sustainable top-line growth.
• Market expansion opportunities driven by regulatory changes (e.g., withdrawal of Andexxa^®), increased use of generic ticagrelor, and rising demand for blood thinner reversal solutions in cardiac surgery.
• Risks remain around timely FDA approval, ongoing turnaround in German operations, and successful execution of cost reduction plans.

Management Commentary

“2025 was a transitional year for our business as we made good progress in four key objectives. We ended the year with positive clinical and commercial momentum for 2026, with a lower cost structure and improved balance sheet to support our growth. Additionally, we continue to make progress with the FDA to align on the content and timing of a new De Novo submission for DrugSorb-ATR and look forward to providing further updates in the future.”
— Dr. Phillip Chan, Chief Executive Officer

Upcoming Events

• Earnings Conference Call: March 25, 2026, at 4:30 PM ET. Webcast link
• Archived recording will be available at CytoSorbents IR site

Disclaimer

This article contains forward-looking statements based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially from those anticipated. Investors should consult CytoSorbents’ latest SEC filings and press releases for a complete description of risk factors. This article is for informational purposes only and does not constitute investment advice. The author and publisher assume no liability for actions taken based on the information contained herein.

View Cytosorbents Corp Historical chart here